← All trials
NCT05552157
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2022
- Primary completion
- Nov 30, 2029
- Completion date
- Mar 31, 2034
- First posted
- Sep 23, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 220
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Washington University in St. LouisLead sponsor
- RocheCollaborator
- GenentechCollaborator
- National Institute on Aging (NIA)Collaborator
- Washington University in St. LouisStudy director
- Alzheimer's AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.